Lead Sponsor

TG Therapeutics, Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Relapsed or refractory B-cell non-Hodgkins Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
•Participants must have received at least one prior line of therapy with an anti-CD20 antibody (i.e. rituximab, ofatumumab, etc.) or an anti-CD20 antibody containing regimen
•Measurable or evaluable Disease
•Eastern Cooperative Oncology Group performance status 0, 1 or 2
•Participants ineligible for high dose or combination chemotherapy + stem cell transplant
•No active or chronic infection of Hepatitis B or C and no history of HIV based on negative serology
•All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®

•Prior chemotherapy, investigational therapy or radiotherapy within 3 weeks of study entry
•Prior autologous or allogeneic stem cell transplantation within 6 months of study entry
•History of severe hypersensitivity or anaphylaxis to prior murine or mouse/human chimeric antibodies, or to any component of ublituximab, or with prior lenalidomide or thalidomide
•Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements
•History of deep vein thrombosis (DVT) or pulmonary embolus (PE) in the six months prior to Day 1 of Cycle 1
•Pregnant women

Related studies

NCT07221500 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

NCT04728893 · Hematologic Malignancies, Waldenstroms Macroglobulinaemia, and more

NCT05672251 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, and more

NCT06846671 · CLL, Chronic Lymphocytic Leukemia

NCT07218341 · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies